Disclaimer: This information is intended for medical professionals and is provided for educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider for any questions regarding a medical condition. Clinical judgment must always be exercised in individual patient care. Drug dosages and regimens should be verified with current prescribing information.

Hyperoxaluria

Overview

• Definition: Hyperoxaluria is a metabolic disorder characterized by excessive excretion of oxalate in the urine, typically defined as urinary oxalate excretion exceeding 40-45 mg/24 hours (0.45-0.5 mmol/24 hours). This elevated oxalate concentration can lead to the formation of calcium oxalate kidney stones and nephrocalcinosis, and in severe cases, systemic deposition of oxalate crystals (oxalosis) in various organs, particularly in individuals with impaired kidney function.

• Epidemiology:

  • Primary Hyperoxaluria (PH): Rare genetic disorders. The estimated prevalence for PH Type 1 (PH1), the most common and severe form, is 1-3 per million population, with an incidence of 1 per 120,000 live births. PH2 and PH3 are even rarer. All forms are autosomal recessive.
  • Secondary Hyperoxaluria: Much more common than PH. Its exact prevalence is challenging to determine as it often occurs in the context of other conditions (e.g., inflammatory bowel disease, bariatric surgery) and may be underdiagnosed. Dietary hyperoxaluria is also common but usually mild.
  • Demographics: PH typically presents in childhood, often with severe manifestations, but adult-onset presentations are also recognized. Secondary hyperoxaluria can affect individuals of any age depending on the underlying cause.

• Classification:

  • Primary Hyperoxaluria (PH): A group of rare, autosomal recessive genetic disorders caused by inherited defects in glyoxylate metabolism, leading to overproduction of endogenous oxalate.
    • PH Type 1 (PH1): Most common (∼80% of PH cases) and severe, caused by mutations in the AGXT gene encoding alanine-glyoxylate aminotransferase (AGT) in peroxisomes. This results in the conversion of glyoxylate to oxalate instead of glycine.
    • PH Type 2 (PH2): Less common (∼10% of PH cases), caused by mutations in the GRHPR gene encoding glyoxylate reductase/hydroxypyruvate reductase (GRHPR). This leads to accumulation of glyoxylate and L-glycerate.
    • PH Type 3 (PH3): Accounts for the remaining PH cases, caused by mutations in the HOGA1 gene encoding 4-hydroxy-2-oxoglutarate aldolase (HOGA1). Leads to accumulation of 4-hydroxy-2-oxoglutarate, a precursor to oxalate.
  • Secondary Hyperoxaluria: Acquired forms of hyperoxaluria due to increased intestinal absorption of oxalate or excessive dietary intake.
    • Enteric Hyperoxaluria: Most common form of severe secondary hyperoxaluria. Occurs due to fat malabsorption (e.g., inflammatory bowel disease, celiac disease, bariatric surgery, pancreatic insufficiency). Unabsorbed fatty acids bind calcium in the gut lumen, leaving free oxalate to be absorbed.
    • Dietary Hyperoxaluria: Caused by excessive intake of oxalate-rich foods (e.g., spinach, rhubarb, nuts, chocolate, tea) or vitamin C (which metabolizes to oxalate). Usually milder than enteric hyperoxaluria.
    • Idiopathic Hyperoxaluria: Mildly elevated urinary oxalate without an identifiable primary or secondary cause; often associated with recurrent calcium oxalate stones.
    • Drug-induced Hyperoxaluria: Ethylene glycol poisoning (metabolized to oxalate), high-dose vitamin C intake (>1-2 g/day), or methoxyflurane anesthesia (historical).

Pathophysiology

• Mechanism:

  • Oxalate Metabolism: Oxalate is a dicarboxylic acid that is an end-product of metabolism. It is primarily derived from endogenous synthesis (glyoxylate, ascorbic acid metabolism) and dietary intake. It is not metabolized further in humans and is exclusively excreted by the kidneys.
  • Primary Hyperoxaluria (PH): Genetic defects lead to enzyme deficiencies in the peroxisomal or cytosolic pathways of glyoxylate metabolism in the liver. This results in the redirection of glyoxylate to oxalate synthesis, leading to systemic overproduction. As kidney function declines, plasma oxalate levels rise sharply, exceeding its solubility and leading to systemic deposition (oxalosis) in bone, heart, retina, skin, and other tissues.
  • Enteric Hyperoxaluria: In conditions causing fat malabsorption, unabsorbed fatty acids reach the colon. These fatty acids bind to intestinal calcium, making it unavailable to bind with dietary oxalate. The increased concentration of free, soluble oxalate in the colon leads to enhanced passive paracellular absorption of oxalate into the bloodstream. Bile acids can also damage colonic mucosa, further increasing permeability to oxalate.
  • Dietary Hyperoxaluria: Directly related to the amount of oxalate consumed. While most dietary oxalate is excreted, high intake can overwhelm renal excretion capacity, especially in individuals with predispositions (e.g., low fluid intake, hypocitraturia).
  • Kidney involvement: High urinary oxalate concentrations lead to supersaturation of calcium oxalate in the urine, promoting crystal formation, aggregation, and deposition in renal tubules (nephrocalcinosis) and urinary tract (nephrolithiasis). This causes tubular injury, inflammation, fibrosis, and progressive chronic kidney disease (CKD), eventually leading to end-stage kidney disease (ESKD).

• Risk Factors:

  • Primary Hyperoxaluria: Family history of PH, consanguinity, recurrent calcium oxalate stones starting in childhood, nephrocalcinosis, early onset ESKD, systemic oxalosis.
  • Secondary Hyperoxaluria:
    • Enteric: Malabsorptive disorders (e.g., Crohn's disease, ulcerative colitis, celiac disease), short bowel syndrome, Roux-en-Y gastric bypass or other bariatric surgeries, chronic pancreatitis, cystic fibrosis.
    • Dietary: High intake of oxalate-rich foods (spinach, rhubarb, beets, nuts, chocolate, strong black tea, collard greens, sweet potatoes), high-dose vitamin C (>1-2 g/day), severe dehydration.
    • Other: Chronic kidney disease (reduces oxalate excretion), history of ethylene glycol ingestion.

• Protective Factors:

  • High Fluid Intake: Dilutes urinary oxalate, reducing supersaturation.
  • Adequate Dietary Calcium: When consumed with oxalate-containing meals, calcium binds oxalate in the gut, reducing absorption.
  • Oxalobacter formigenes: A gut bacterium that degrades oxalate, reducing its absorption. Absence or depletion (e.g., due to antibiotics) may increase oxalate absorption.
  • Dietary Restriction (for secondary forms): Limiting high-oxalate foods and high-dose vitamin C.
  • Citrate: Urinary citrate acts as an inhibitor of calcium oxalate crystal formation.
  • Magnesium: May complex with oxalate in the gut.

Clinical Presentation

Signs and Symptoms

• Cardinal Features:

  • Recurrent Nephrolithiasis: Calcium oxalate kidney stones, often multiple and bilateral, starting at a young age (especially in PH).
  • Nephrocalcinosis: Diffuse calcification of renal parenchyma, frequently seen in PH and severe enteric hyperoxaluria, leading to progressive kidney damage.
  • Progressive Chronic Kidney Disease (CKD): Gradual decline in kidney function due to stone disease and nephrocalcinosis, often culminating in End-Stage Kidney Disease (ESKD).

• Early Signs:

  • Infancy/Childhood (PH): Failure to thrive, recurrent urinary tract infections (UTIs), hematuria, "gravel" in diapers (calcium oxalate crystals), poor growth, irritability, acute renal failure.
  • Adolescence/Adulthood (PH/Secondary): Recurrent episodes of renal colic, gross or microscopic hematuria, symptoms of UTI, flank pain.
  • For PH1, ~10% present with ESKD and systemic oxalosis in infancy ("infantile oxalosis").

• Advanced Signs: (Often associated with systemic oxalosis, typically seen in PH or severe secondary hyperoxaluria after ESKD develops)

  • Skeletal: Bone pain, pathological fractures, osteosclerosis, pseudogout-like arthritis (oxalate deposition in joints and cartilage).
  • Cardiovascular: Conduction abnormalities (heart block), cardiomyopathy (restrictive), congestive heart failure due to myocardial oxalate deposition.
  • Ocular: Retinal oxalosis (punctate white lesions), visual impairment.
  • Dermatological: Livedo reticularis, skin discoloration, chronic ulcers.
  • Peripheral Neuropathy: Autonomic or sensory neuropathy.
  • Hematologic: Anemia refractory to erythropoietin (due to marrow oxalosis), thrombotic microangiopathy.
  • Dental: Enamel hypoplasia.

• Atypical Presentations:

  • Late-onset PH (adult presentation, milder phenotype).
  • Isolated nephrocalcinosis without stone formation.
  • Initial presentation as unexplained anemia or cardiomyopathy in advanced kidney disease.
  • Unexplained sudden cardiac death.

Physical Examination

• Inspection:

  • General: Pallor (anemia), signs of chronic illness (poor growth in children), uremic frost (very advanced ESKD).
  • Skin: Livedo reticularis, violaceous discoloration, subcutaneous nodules (oxalate deposits).
  • Eyes: Retinal findings on fundoscopy (white dots, crystalline deposits).
  • Joints: Swelling, tenderness, signs of inflammation (pseudogout).
  • Growth: Stunted growth, short stature (especially in children with PH).

• Palpation:

  • Abdomen: Costovertebral angle tenderness (renal colic), palpable kidney (hydronephrosis), enlarged liver/spleen (rare, but can occur with systemic oxalosis).
  • Bones/Joints: Tenderness, warmth, swelling.

• Special Tests:

  • Cardiac Auscultation: Murmurs, gallop rhythms (S3, S4) indicating cardiomyopathy or heart failure.
  • Neurological Exam: Assessment for peripheral neuropathy (sensory deficits, decreased reflexes).
  • Ophthalmologic Exam: Fundoscopy to identify retinal oxalate deposits.

Diagnostic Approach

History Taking

• Key Questions:

  • Kidney Stone History: Age of first stone, frequency, number, composition (if known), family history of stones.
  • Urinary Symptoms: Hematuria (gross/microscopic), dysuria, frequency, flank pain, history of UTIs.
  • General Health: Growth and development (pediatric), fatigue, bone pain, joint pain.
  • Family History: Kidney disease, kidney stones, dialysis, or early death in family members (suggestive of PH).
  • Dietary History: Intake of high-oxalate foods, high-dose vitamin C supplements.
  • Gastrointestinal History: Malabsorption, chronic diarrhea, inflammatory bowel disease (Crohn's, UC), celiac disease, history of bariatric surgery (especially Roux-en-Y gastric bypass), pancreatic insufficiency.
  • Medication History: Vitamin C supplements, laxatives, antibiotics (affecting gut flora).
  • Past Medical History: Renal failure, dialysis, prior kidney biopsies.

• Red Flags:

  • Recurrent calcium oxalate kidney stones in childhood.
  • Nephrocalcinosis in a young patient.
  • Progressive CKD of unknown etiology.
  • Family history of kidney disease requiring dialysis/transplantation.
  • Systemic symptoms (e.g., bone pain, cardiac issues, anemia) alongside kidney disease, especially if severe or unexplained.
  • Kidney stone formation despite standard preventative measures.

Laboratory Tests

• First-Line:

  • 24-Hour Urine Oxalate Excretion: Key diagnostic test.
    • Normal: <40-45 mg/24 hours (<0.45-0.5 mmol/24 hours).
    • Hyperoxaluria: >40-45 mg/24 hours.
    • Severe Hyperoxaluria (often PH): >100 mg/24 hours (>1.13 mmol/24 hours).
    • Interpretation: Also measure urinary calcium, citrate, creatinine, sodium, uric acid, and volume. Multiple collections may be needed. Ensure proper collection (avoid high oxalate foods 24-48h prior for secondary hyperoxaluria assessment if dietary cause is suspected, but for PH, the endogenous overproduction means dietary restriction won't normalize levels).
  • Plasma Oxalate (POx): Crucial in patients with CKD GFR <30 mL/min/1.73m², as urinary excretion becomes unreliable.
    • Normal: <5 µmol/L (<0.45 mg/L).
    • Elevated in CKD: 10-20 µmol/L in ESKD patients.
    • Significantly Elevated in PH with ESKD: Often >50-100 µmol/L (a strong indicator of PH).
    • Note: Plasma oxalate testing is specialized and should be sent to a reference lab.
  • Serum Creatinine and eGFR: Assess kidney function.
  • Urinalysis: Hematuria, crystalluria (calcium oxalate monohydrate or dihydrate crystals), proteinuria.

• Confirmatory (for PH diagnosis):

  • Genetic Testing: Definitive diagnosis. Panel testing for AGXT, GRHPR, and HOGA1 genes. This is the preferred method for confirming PH.
  • Liver Biopsy (with enzyme assay): Historically used, now reserved for cases where genetic testing is inconclusive or to assess AGT enzyme activity (for PH1 diagnosis), especially if considering liver transplantation. Requires specialized histopathology.
  • Urinary Glycolate (PH1) and L-Glycerate (PH2): Metabolite excretion analysis in urine.
    • PH1: Markedly elevated urinary glycolate.
    • PH2: Markedly elevated urinary L-glycerate (often >200 mmol/mol creatinine).
    • PH3: Elevated urinary HOGA.
    • Note: These tests are specialized and performed in reference laboratories.

• Monitoring:

  • 24-Hour Urine Oxalate: To assess treatment response (e.g., pyridoxine, novel therapies) and disease progression.
  • Plasma Oxalate: Crucial for monitoring effectiveness of therapies in patients with CKD/ESKD and for pre/post-transplant assessment.
  • Renal Function Tests: Serum creatinine, eGFR, urine protein:creatinine ratio (UPCR) to monitor CKD progression.
  • Imaging: Regular kidney ultrasound to assess for stone burden, nephrocalcinosis, and hydronephrosis.

Imaging

• Recommended:

  • Renal Ultrasound (US): First-line imaging. Identifies nephrolithiasis, nephrocalcinosis (highly suggestive of PH or severe secondary hyperoxaluria, particularly in children), hydronephrosis, and kidney size. Can monitor stone burden and calcification progression.
  • Kidney, Ureter, Bladder (KUB) X-ray: Detects radiopaque calcium oxalate stones. Useful for monitoring stone growth.
  • Non-Contrast CT KUB: Gold standard for detecting and characterizing kidney stones, extent of nephrocalcinosis, and ruling out other causes of renal colic. Low-dose protocols are preferred.

• Advanced (for assessing systemic oxalosis or specific situations):

  • Echocardiogram: Assess for cardiomyopathy, especially restrictive cardiomyopathy, and cardiac oxalate deposits in advanced disease.
  • Bone Scan (Technetium-99m Methylene Diphosphonate, Tc-99m MDP): Can detect oxalate deposition in bones, which appears as increased uptake, particularly in epiphyses and metaphyses.
  • Cardiac MRI: More sensitive for detecting myocardial oxalate deposition than echocardiography.
  • Retinal Photography/Fundoscopy: To visualize retinal oxalate deposits.
  • Biopsies:
    • Bone Marrow Biopsy: To evaluate for oxalate deposits in patients with refractory anemia.
    • Kidney Biopsy: To evaluate degree of nephrocalcinosis, interstitial fibrosis, and tubular atrophy.
    • Other Tissue Biopsies: Skin, nerve, heart, or other affected organs if clinical suspicion of systemic oxalosis is high and other diagnostic tests are inconclusive.

Management

Acute Management

• Immediate (for acute renal colic/kidney stones):

  • Pain Management: NSAIDs (ketorolac 30-60 mg IV/IM or ibuprofen 400-800 mg PO) or opioids (morphine 2-4 mg IV) for acute renal colic.
  • Hydration: IV fluids for dehydration or inability to tolerate oral intake.
  • Anti-emetics: Ondansetron 4-8 mg IV/PO for nausea/vomiting.

• Stabilization (for acute kidney injury or obstruction):

  • Urgent Urological Consultation: For obstructing stones causing hydronephrosis, infection, or acute kidney injury. Percutaneous nephrostomy or ureteral stent placement may be necessary for urinary diversion.
  • Correction of Electrolyte Imbalances: Manage hyperkalemia, metabolic acidosis if present due to AKI.
  • Dialysis (in severe AKI/ESKD with severe oxalosis): If patient has severe AKI or ESKD with high plasma oxalate levels and systemic symptoms, hemodialysis may be initiated to remove oxalate. However, conventional hemodialysis is inefficient for oxalate removal; intensive, prolonged hemodialysis (daily or every other day) is often required.

• Emergency (for systemic oxalosis crisis, especially in PH):

  • Intensified Dialysis: For patients with severe systemic oxalosis and ESKD, daily or even twice-daily hemodialysis for prolonged periods (e.g., 6-8 hours per session) may be necessary to reduce plasma oxalate burden while awaiting transplantation. This requires close monitoring for electrolyte shifts and fluid balance.

Chronic Management

• Pharmacological:

  • Pyridoxine (Vitamin B6): First-line for PH1 patients, particularly those who are pyridoxine-responsive.
    • Mechanism: Pyridoxine is a cofactor for AGT. In some AGXT mutations, AGT misfolds and cannot bind pyridoxine effectively; high-dose pyridoxine can act as a pharmacological chaperone, improving AGT folding and function, thereby reducing oxalate production.
    • Dosage: Typically 5-20 mg/kg/day orally, up to a maximum of 500 mg/day. Start with 5 mg/kg/day and titrate based on urinary oxalate reduction.
    • Responsiveness: Approximately 30-50% of PH1 patients are pyridoxine-responsive (defined as >30% reduction in urinary oxalate or normalization of levels). Response should be assessed after 3-6 months. PH2 and PH3 are not pyridoxine-responsive.
    • Monitoring: Close monitoring of urinary oxalate (24-hour collection) and plasma oxalate (if CKD is present) is essential. Side effects are generally mild, but peripheral neuropathy can occur with very high doses (rarely with doses <500 mg/day).
  • Urinary Crystallization Inhibitors:
    • Potassium Citrate: Alkalinizes urine and increases urinary citrate, which inhibits calcium oxalate crystallization.
      • Dosage: Typically 20-60 mEq/day orally, divided into 2-3 doses, adjusted to achieve a urinary pH of 6.5-7.0.
    • Thiazide Diuretics (e.g., Hydrochlorothiazide, Chlorthalidone): Reduce urinary calcium excretion, thereby reducing the supersaturation of calcium oxalate. Used primarily for patients with concurrent hypercalciuria, but can be considered generally to reduce calcium oxalate risk.
      • Dosage: Hydrochlorothiazide 25-50 mg/day orally.
  • Oxalate-Binding Agents (for enteric/dietary hyperoxaluria):
    • Calcium Carbonate/Calcium Citrate: Taken with meals to bind dietary oxalate in the gut, reducing absorption.
      • Dosage: 1-2 grams of elemental calcium per day, divided with meals. Avoid excessive calcium, which can promote hypercalciuria.
    • Cholestyramine: Bile acid sequestrant that can also bind oxalate.
      • Dosage: 4g 1-3 times daily with meals.
  • Novel Therapies (for PH1 and PH2):
    • Lumasiran (Oxlumo®): A small interfering RNA (siRNA) therapeutic.
      • Mechanism: Targets the messenger RNA (mRNA) for glycolate oxidase (GO) in the liver, an enzyme upstream of AGXT. By reducing GO, less glyoxylate is produced, thus reducing oxalate production in PH1.
      • Dosage: Subcutaneous injection. Initial loading phase: 3 mg/kg monthly for 3 doses; maintenance phase: 3 mg/kg every 3 months. Dosing adjusted for body weight and age.
      • Indications: Approved for PH1 in adults and children of all ages. Significantly reduces urinary and plasma oxalate levels, slowing CKD progression.
    • Nedosiran (Rivadoux®): Another siRNA therapeutic.
      • Mechanism: Targets the mRNA for lactate dehydrogenase (LDHA) in the liver, which is responsible for converting glyoxylate to oxalate. Reduces oxalate overproduction.
      • Dosage: Subcutaneous injection. Initial loading phase: 6.8 mg/kg monthly for 3 doses; maintenance phase: 6.8 mg/kg every month. Dosing adjusted for body weight.
      • Indications: Approved for PH1 and PH2 in adults and children 6 years and older. Reduces urinary and plasma oxalate levels.
  • Orally Administered Oxalate-Degrading Enzymes/Bacteria:
    • Reloxaliase: Recombinant oxalate degrading enzyme, being developed for enteric hyperoxaluria.
    • Oxalobacter formigenes-based therapeutics: Oral formulations of this bacterium are under investigation to degrade oxalate in the gut. Not yet widely available.

• Non-pharmacological:

  • High Fluid Intake: Crucial for all forms of hyperoxaluria. Patients should aim for a urine output of >2.5-3 liters per day (e.g., 2-3 glasses of water every 2 hours while awake).
  • Dietary Modifications:
    • Low Oxalate Diet (for secondary/dietary hyperoxaluria): Restrict foods very high in oxalate (e.g., spinach, rhubarb, beets, almonds, cashews, chocolate, black tea, collard greens, sweet potatoes). This is less impactful for PH, where endogenous production is the main issue.
    • Adequate Dietary Calcium: Ensure adequate calcium intake (1000-1200 mg/day) from food, preferably with meals, to bind oxalate in the gut. Avoid severe calcium restriction.
    • Avoid High-Dose Vitamin C: Limit intake to <1-2 g/day.
    • Moderate Protein Intake: High animal protein can increase acid load and calcium excretion.
    • Sodium Restriction: High sodium intake increases calcium excretion.
  • Management of Malabsorption (for enteric hyperoxaluria):
    • Low Fat Diet: Reduces free fatty acids available to bind calcium.
    • Medium-Chain Triglycerides (MCTs): Used as an energy source, as they are absorbed directly and do not interfere with calcium binding.
    • Pancreatic Enzyme Replacement Therapy: For pancreatic insufficiency.
    • Treat Underlying GI Disease: Optimize management of Crohn's disease, celiac disease, etc.

• Monitoring:

  • Regular (e.g., every 3-6 months) 24-hour urine oxalate and plasma oxalate (if CKD GFR <30).
  • Monitoring of renal function (eGFR, serum creatinine).
  • Annual or biennial renal ultrasound to assess nephrocalcinosis and stone burden.
  • Cardiovascular (ECG, echocardiogram) and bone imaging (bone scan) as indicated to monitor for systemic oxalosis.

Treatment Algorithms

• First-Line:

  • Suspected PH (high oxalate, nephrocalcinosis, early-onset stones):
    1. Confirm diagnosis with genetic testing.
    2. High fluid intake (>3 L/day urine output target).
    3. Potassium citrate (adjust to urinary pH 6.5-7.0).
    4. For PH1: Initiate pyridoxine (5-20 mg/kg/day, max 500 mg/day). Assess response.
    5. For PH1 (regardless of pyridoxine response) and PH2: Initiate Lumasiran (PH1) or Nedosiran (PH1/PH2) as per approved indications.
  • Enteric Hyperoxaluria:
    1. Address underlying malabsorption (e.g., treat IBD, pancreatic enzymes).
    2. Low-fat diet, adequate dietary calcium with meals.
    3. High fluid intake, potassium citrate.
    4. Oxalate-binding agents (calcium carbonate with meals, cholestyramine).
  • Dietary Hyperoxaluria:
    1. Dietary counseling (low oxalate foods, adequate calcium, avoid high-dose Vitamin C).
    2. High fluid intake.
    3. Consider potassium citrate if persistent.

• Second-Line:

  • Failed pyridoxine/siRNA or non-candidates:
    • Consider adjunctive therapies.
  • Advanced CKD/ESKD in PH:
    • Pre-emptive Transplantation:
      • PH1: Combined liver-kidney transplantation is often required, as the liver is the site of the enzyme defect. Living donor liver transplantation can be considered. Liver transplant alone can be considered if diagnosed very early with excellent kidney function.
      • PH2/PH3: Kidney transplantation alone may be sufficient, as the enzyme defect is less severe or renal damage is the primary issue. However, if diagnosed post-ESKD, a period of intensive dialysis to clear oxalate may be necessary before kidney transplant to prevent rapid graft failure due to oxalate deposition.
    • Intensive Dialysis: Daily or extended hemodialysis for ESKD patients to manage plasma oxalate until transplantation.

• Refractory Cases:

  • Persistent high oxalate despite all medical therapies:
    • Re-evaluate diagnosis, adherence to therapy, and underlying conditions.
    • Consider specialized centers with expertise in rare kidney diseases and metabolic disorders.
    • For PH with ESKD, refer for urgent transplant evaluation (combined liver-kidney for PH1, kidney for PH2/PH3 with careful oxalate management).
  • Recurrent symptomatic stones despite optimal medical therapy:
    • Regular urological follow-up, consideration of endoscopic stone removal (ureteroscopy, percutaneous nephrolithotomy) as needed.
    • Explore newer research treatments or clinical trials.

Complications

• Common:

  • Recurrent Nephrolithiasis: Calcium oxalate kidney stones, leading to repeated episodes of renal colic, hematuria, and UTIs.
  • Nephrocalcinosis: Diffuse calcification of the renal parenchyma, impairing kidney function.
  • Chronic Kidney Disease (CKD): Progressive loss of kidney function, often leading to ESKD.
  • Urinary Tract Infections (UTIs): Due to stones and stasis.

• Serious:

  • End-Stage Kidney Disease (ESKD): Requires dialysis or transplantation. In PH, ESKD significantly accelerates systemic oxalate deposition.
  • Systemic Oxalosis: Widespread oxalate crystal deposition in non-renal organs, occurring predominantly in PH or severe secondary hyperoxaluria after ESKD.
    • Cardiomyopathy/Conduction Defects: Can lead to heart failure and sudden cardiac death.
    • Bone Marrow Oxalosis: Causes refractory anemia and osteosclerosis, pathological fractures.
    • Peripheral Neuropathy.
    • Ocular Oxalosis: Visual impairment.
    • Growth Failure: In children.

• Long-term:

  • Dependence on dialysis and/or transplantation.
  • Persistent risk of graft failure in kidney transplant recipients if PH is not addressed (e.g., without liver transplant for PH1).
  • Ongoing need for strict fluid and dietary management.
  • Chronic pain from stones or bone oxalosis.
  • Reduced quality of life due to disease burden and complications.

Prognosis

• Factors:

  • Type of Hyperoxaluria: PH1 has the worst prognosis, often progressing to ESKD in childhood or early adulthood. PH2 and PH3 generally have a milder course with slower CKD progression, but can still lead to ESKD. Secondary hyperoxaluria prognosis depends heavily on the underlying cause and effective management.
  • Age of Onset/Diagnosis: Earlier onset of PH is associated with more aggressive disease and worse prognosis. Infantile PH1 often leads to ESKD within the first year of life.
  • Pyridoxine Responsiveness (for PH1): Responsive patients have a better prognosis, often delaying or preventing ESKD.
  • Compliance with Therapy: Adherence to fluid intake, dietary restrictions, and medications is crucial for slowing disease progression and preventing complications.
  • Presence of Systemic Oxalosis: Indicates advanced disease and significantly worsens prognosis, especially cardiac involvement.
  • Access to Transplantation: Liver-kidney transplantation (for PH1) significantly improves survival and quality of life for ESKD patients. Prompt kidney transplantation (for PH2/3) after intensive oxalate removal is also crucial.
  • Novel Therapies (siRNA): Lumasiran and Nedosiran have shown significant reductions in oxalate levels, dramatically improving the prognosis for PH1 and PH2 patients, particularly if initiated early.

• Survival:

  • Without treatment, PH1 patients often reach ESKD by late childhood or early adulthood. Survival rates were historically poor for ESKD patients with systemic oxalosis without transplantation.
  • With combined liver-kidney transplantation, 5-year patient survival rates for PH1 are high (~70-90%).
  • Prognosis for PH2 and PH3 is generally better, with a lower risk of systemic oxalosis and often slower progression to ESKD.
  • The advent of siRNA therapies is expected to significantly improve long-term outcomes for PH1 and PH2 by preventing or delaying ESKD and systemic oxalosis.

• Quality of Life:

  • Significantly impacted by recurrent kidney stones, CKD symptoms, dialysis, and systemic oxalosis.
  • Successful transplantation or effective medical management (especially with novel therapies) can dramatically improve QoL.
  • Children often experience growth failure and developmental delays, requiring comprehensive care.

Prevention

• Primary (Preventing initial occurrence):

  • Genetic Counseling: For families with a known history of PH, to identify carriers and discuss reproductive options (e.g., preimplantation genetic diagnosis).
  • Dietary Guidance: For individuals at risk of secondary hyperoxaluria (e.g., bariatric surgery patients, individuals with IBD). Education on appropriate calcium intake with meals, avoidance of excessive oxalate-rich foods and high-dose vitamin C.
  • Judicious Use of Antibiotics: To preserve Oxalobacter formigenes in the gut, especially in at-risk individuals.
  • Fluid Intake: Encourage adequate hydration in the general population to prevent kidney stones.

• Secondary (Early detection and intervention):

  • Screening:
    • 24-hour urine oxalate measurement for any child or young adult presenting with recurrent calcium oxalate stones, nephrocalcinosis, or unexplained CKD.
    • Consider screening patients with malabsorptive disorders or bariatric surgery for hyperoxaluria.
  • Prompt Diagnosis and Treatment: Early initiation of specific therapies (pyridoxine, siRNA therapies) in PH to prevent progressive kidney damage and systemic oxalosis.
  • Aggressive Stone Management: Prompt removal of obstructing stones to prevent further kidney damage.
  • Optimization of Underlying Conditions: Strict control of IBD, celiac disease, or other malabsorptive states.

• Tertiary (Preventing complications and progression):

  • Strict Adherence to Medical Therapies: Consistent use of fluid therapy, potassium citrate, pyridoxine, and novel siRNA drugs.
  • Regular Monitoring: Close follow-up of urinary oxalate, plasma oxalate, kidney function, and imaging (ultrasound, echocardiogram) to detect early signs of progression or systemic oxalosis.
  • Timely Referral for Transplantation: Early evaluation for liver-kidney or kidney transplantation for PH patients approaching ESKD to prevent severe systemic oxalosis and improve outcomes.
  • Multidisciplinary Care: Involve nephrologists, urologists, geneticists, dietitians, and transplant specialists.

Special Populations

• Pediatric:

  • More Severe Presentation: Often presents in infancy or early childhood with severe nephrocalcinosis, recurrent stones, and rapid progression to ESKD and systemic oxalosis (infantile oxalosis).
  • Diagnostic Challenge: Suspicion requires high index. Failure to thrive, recurrent UTIs, and unexplained AKI/CKD should prompt investigation.
  • Urgent Intervention: Early diagnosis and initiation of therapies (e.g., Lumasiran, pyridoxine) are critical to preserve kidney function.
  • Fluid Management: Careful fluid management due to risk of fluid overload in infants.
  • Nutritional Support: Crucial for growth and development.

• Geriatric:

  • Comorbidities: Often have multiple comorbidities (e.g., cardiovascular disease, diabetes) that can complicate management and increase surgical risks.
  • Drug Interactions: Increased risk of drug interactions with polypharmacy.
  • Reduced Renal Reserve: May experience faster decline in kidney function with stones.
  • Lower Oxalate Excretion: Normal age-related decline in GFR can lead to higher plasma oxalate levels even with mild hyperoxaluria.
  • Less Aggressive PH: Adult-onset PH often has a milder phenotype, potentially slower progression.

• Pregnancy:

  • Limited Data: Safety of most hyperoxaluria medications during pregnancy is not well-established.
  • Fluid Management: Increased fluid needs during pregnancy.
  • Dietary Adjustments: Careful dietary counseling.
  • Monitoring: Close monitoring of kidney function and urinary oxalate.
  • Medication Review: Pyridoxine is generally safe. SiRNA therapies like Lumasiran and Nedosiran are category C (animal studies show adverse effects or no human data, but potential benefits may outweigh risks). Weigh risks/benefits with a specialist.
  • Risk of Obstruction: Enlarged uterus can increase risk of urinary stasis and stone formation.

• Comorbidities:

  • Inflammatory Bowel Disease (IBD): Optimize IBD treatment to reduce inflammation and malabsorption. May require specific dietary interventions and oxalate binders.
  • Bariatric Surgery: High risk of enteric hyperoxaluria. Patients require lifelong monitoring for hyperoxaluria and kidney stones. Aggressive fluid intake and calcium supplementation with meals are essential.
  • Chronic Kidney Disease (CKD): Management of hyperoxaluria becomes more complex as GFR declines. Plasma oxalate becomes the primary monitoring parameter. Dialysis strategies must be tailored for oxalate removal.

Clinical Pearls

• Diagnostic:

  • Think PH in "young stone formers": Any child or young adult with recurrent calcium oxalate stones or nephrocalcinosis should be evaluated for Primary Hyperoxaluria.
  • Plasma Oxalate for CKD: 24-hour urine oxalate is unreliable in GFR <30 mL/min/1.73m². Always order plasma oxalate in these patients to assess oxalate burden.
  • Genetic Testing is Key: It's the definitive diagnostic tool for PH and is becoming more accessible.
  • Don't Forget Secondary Causes: A thorough dietary and GI history is crucial to identify enteric or dietary hyperoxaluria.

• Treatment:

  • Hydration is Paramount: The most important single intervention for all forms of hyperoxaluria is high fluid intake to achieve a dilute urine.
  • Pyridoxine Trial in PH1: Always initiate a pyridoxine trial in newly diagnosed PH1 patients, as responders can have a dramatically better prognosis.
  • Novel Therapies are Game-Changers: Lumasiran and Nedosiran represent a paradigm shift for PH1 (and PH2 for Nedosiran), significantly reducing oxalate production. Early initiation is vital.
  • Calcium Intake: For enteric hyperoxaluria, ensure adequate calcium intake with meals, not calcium restriction.
  • Transplantation Timing: For PH1 patients with ESKD, combined liver-kidney transplant is crucial. For PH2/3, intensive dialysis before kidney transplant is essential to debulk oxalate and protect the new kidney.

• Pitfalls:

  • Misdiagnosing PH as Idiopathic Stone Disease: Delaying PH diagnosis leads to irreversible kidney damage and systemic oxalosis.
  • Over-restricting Calcium in Diet: This can worsen enteric hyperoxaluria by leaving more free oxalate in the gut.
  • Underestimating Systemic Oxalosis: Ignoring non-renal symptoms in ESKD patients with hyperoxaluria can lead to severe cardiac or bone complications.
  • Inadequate Oxalate Removal in ESKD: Conventional dialysis is insufficient. Patients with PH and ESKD require intensive, prolonged dialysis.
  • Failure to Monitor Treatment Response: Not regularly checking 24-hour urine or plasma oxalate can lead to ineffective therapy.

Recent Updates

• Guidelines:

  • 2021 European Renal Association – European Society for Paediatric Nephrology (ERA-EDTA/ESPN) Guidelines for the Diagnosis and Treatment of Primary Hyperoxaluria: Emphasize early genetic diagnosis, the role of pyridoxine testing, and the integration of novel RNAi therapies. They provide detailed algorithms for management including transplantation.
  • American Urological Association (AUA) Guidelines: Incorporate hyperoxaluria as a key metabolic abnormality to assess in recurrent stone formers.

• Evidence:

  • SiRNA Therapies:
    • Lumasiran: Phase 3 trials (ILLUMINATE-A, -B, -C) demonstrated significant and sustained reductions in urinary and plasma oxalate in PH1 patients, including infants and young children, leading to FDA and EMA approval. It has shown to slow the decline in eGFR.
    • Nedosiran: Phase 3 trial (ENVISION) showed similar efficacy in reducing urinary oxalate in PH1 and PH2 patients, leading to FDA approval.
  • Improved Understanding of PH3: While generally milder, PH3 can also cause significant stone disease and CKD, underscoring the need for careful monitoring.
  • Oral Oxalate-Degrading Enzymes/Probiotics: Ongoing research into reloxaliase (an oxalate-degrading enzyme for enteric hyperoxaluria) and oral Oxalobacter formigenes preparations.

• Controversies:

  • Optimal Timing of Liver vs. Liver-Kidney Transplant for PH1: Debates continue regarding whether isolated liver transplant should be considered in early stages of PH1 (before ESKD) or if combined liver-kidney is always superior given the risk of ongoing renal oxalate injury even post-liver transplant.
  • Role of Oxalobacter formigenes Supplementation: While promising, the efficacy and appropriate use of Oxalobacter formigenes or other probiotics for oxalate degradation are still under investigation.
  • Long-term Efficacy and Safety of siRNA Therapies: While current data are excellent, long-term safety profiles, particularly concerning potential off-target effects, and sustained efficacy remain areas of ongoing study.
  • Management of PH in Advanced CKD with High Systemic Oxalosis Burden: The optimal intensity and duration of dialysis prior to transplantation, and strategies to prevent oxalate deposition in the transplanted kidney, are still areas of active discussion and individualized clinical judgment.

Key References

• Guidelines:

  • Hoppe, B., et al. (2021). Diagnostic and therapeutic recommendations for primary hyperoxaluria: a Consensus Statement. Kidney International, 100(4), 780-798. [ERA-EDTA/ESPN Guidelines]
  • Cochat, P., et al. (2012). Primary hyperoxaluria Type 1: indications for and timing of combined liver-kidney transplantation. Nephrology Dialysis Transplantation, 27(9), 3355-3363.

• Studies:

  • Garrelfs, S.F., et al. (2021). Lumasiran, an RNAi Therapeutic, in Primary Hyperoxaluria Type 1. New England Journal of Medicine, 384(13), 1216-1226. (ILLUMINATE-A trial)
  • Langman, C.B., et al. (2020). Nedosiran in Patients with Primary Hyperoxaluria: The Phase 2 PHYOX2 Randomized Clinical Trial. Clinical Journal of the American Society of Nephrology, 15(12), 1766-1776.
  • Milliner, D.S., et al. (2018). Results of a phase 3 pivotal trial to assess the efficacy and safety of a recombinant oxalate degrading enzyme (Reloxaliase) in patients with enteric hyperoxaluria (NCT02766861). Nephrology Dialysis Transplantation, 33(Suppl 3), iii554.

• Reviews:

  • Hoppe, B. (2019). An update on primary hyperoxaluria. Nature Reviews Nephrology, 15(7), 415-422.
  • Kopp, K.D., et al. (2021). Hyperoxaluria. Nephrology Dialysis Transplantation, 36(Supplement_2), ii3-ii14.
  • Lorenz, E.C., et al. (2016). Hyperoxaluria: an update on mechanisms and treatments. Nature Reviews Nephrology, 12(9), 533-544.